Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma

M. Wenzel, N. Siron, C. Collà Ruvolo, L. Nocera, C. Würnschimmel, Z. Tian, SF. Shariat, F. Saad, A. Briganti, D. Tilki, S. Banek, LA. Kluth, FC. Roos, FKH. Chun, PI. Karakiewicz

. 2022 ; 33 (1) : 25-35. [pub] 20210902

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011433
E-zdroje Online Plný text

NLK ProQuest Central od 1999-02-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2005-02-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1999-02-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1999-02-01 do Před 1 rokem
Public Health Database (ProQuest) od 1999-02-01 do Před 1 rokem

Odkazy

PubMed 34476653
DOI 10.1007/s10552-021-01493-3
Knihovny.cz E-zdroje

PURPOSE: To compare Cancer-specific mortality (CSM) in patients with Squamous cell carcinoma (SCC) vs. non-SCC penile cancer, since survival outcomes may differ between histological subtypes. METHODS: Within the Surveillance, Epidemiology and End Results database (2004-2016), penile cancer patients of all stages were identified. Temporal trend analyses, cumulative incidence and Kaplan-Meier plots, multivariable Cox regression and Fine and Gray competing-risks regression analyses tested for CSM differences between non-SCC vs. SCC penile cancer patients. RESULTS: Of 4,120 eligible penile cancer patients, 123 (3%) harbored non-SCC vs. 4,027 (97%) SCC. Of all non-SCC patients, 51 (41%) harbored melanomas, 42 (34%) basal cell carcinomas, 10 (8%) adenocarcinomas, eight (6.5%) skin appendage malignancies, six (5%) epithelial cell neoplasms, two (1.5%) neuroendocrine tumors, two (1.5%) lymphomas, two (1.5%) sarcomas. Stage at presentation differed between non-SCC vs. SCC. In temporal trend analyses, non-SCC diagnoses neither decreased nor increased over time (p > 0.05). After stratification according to localized, locally advanced, and metastatic stage, no CSM differences were observed between non-SCC vs. SCC, with 5-year survival rates of 11 vs 11% (p = 0.9) for localized, 33 vs. 37% (p = 0.4) for locally advanced, and 1-year survival rates of 37 vs. 53% (p = 0.9) for metastatic penile cancer, respectively. After propensity score matching for patient and tumor characteristics and additional multivariable adjustment, no CSM differences between non-SCC vs. SCC were observed. CONCLUSION: Non-SCC penile cancer is rare. Although exceptions exist, on average, non-SCC penile cancer has comparable CSM as SCC penile cancer patients, after stratification for localized, locally invasive, and metastatic disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011433
003      
CZ-PrNML
005      
20220506125828.0
007      
ta
008      
220425s2022 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10552-021-01493-3 $2 doi
035    __
$a (PubMed)34476653
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Wenzel, Mike $u Division of Urology, Cancer Prognostictables and Health Outcomes Unit, University of Montréal Health Center, Montreal, QC, Canada. Mike.Wenzel@kgu.de $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Theodor- Stern Kai 7, 60590, Frankfurt am Main, Germany. Mike.Wenzel@kgu.de $1 https://orcid.org/0000000243380889
245    10
$a Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma / $c M. Wenzel, N. Siron, C. Collà Ruvolo, L. Nocera, C. Würnschimmel, Z. Tian, SF. Shariat, F. Saad, A. Briganti, D. Tilki, S. Banek, LA. Kluth, FC. Roos, FKH. Chun, PI. Karakiewicz
520    9_
$a PURPOSE: To compare Cancer-specific mortality (CSM) in patients with Squamous cell carcinoma (SCC) vs. non-SCC penile cancer, since survival outcomes may differ between histological subtypes. METHODS: Within the Surveillance, Epidemiology and End Results database (2004-2016), penile cancer patients of all stages were identified. Temporal trend analyses, cumulative incidence and Kaplan-Meier plots, multivariable Cox regression and Fine and Gray competing-risks regression analyses tested for CSM differences between non-SCC vs. SCC penile cancer patients. RESULTS: Of 4,120 eligible penile cancer patients, 123 (3%) harbored non-SCC vs. 4,027 (97%) SCC. Of all non-SCC patients, 51 (41%) harbored melanomas, 42 (34%) basal cell carcinomas, 10 (8%) adenocarcinomas, eight (6.5%) skin appendage malignancies, six (5%) epithelial cell neoplasms, two (1.5%) neuroendocrine tumors, two (1.5%) lymphomas, two (1.5%) sarcomas. Stage at presentation differed between non-SCC vs. SCC. In temporal trend analyses, non-SCC diagnoses neither decreased nor increased over time (p > 0.05). After stratification according to localized, locally advanced, and metastatic stage, no CSM differences were observed between non-SCC vs. SCC, with 5-year survival rates of 11 vs 11% (p = 0.9) for localized, 33 vs. 37% (p = 0.4) for locally advanced, and 1-year survival rates of 37 vs. 53% (p = 0.9) for metastatic penile cancer, respectively. After propensity score matching for patient and tumor characteristics and additional multivariable adjustment, no CSM differences between non-SCC vs. SCC were observed. CONCLUSION: Non-SCC penile cancer is rare. Although exceptions exist, on average, non-SCC penile cancer has comparable CSM as SCC penile cancer patients, after stratification for localized, locally invasive, and metastatic disease.
650    12
$a adenokarcinom $7 D000230
650    12
$a spinocelulární karcinom $x epidemiologie $7 D002294
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory penisu $x epidemiologie $7 D010412
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
700    1_
$a Siron, Nicolas $u Division of Urology, Cancer Prognostictables and Health Outcomes Unit, University of Montréal Health Center, Montreal, QC, Canada
700    1_
$a Collà Ruvolo, Claudia $u Division of Urology, Cancer Prognostictables and Health Outcomes Unit, University of Montréal Health Center, Montreal, QC, Canada $u Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy
700    1_
$a Nocera, Luigi $u Division of Urology, Cancer Prognostictables and Health Outcomes Unit, University of Montréal Health Center, Montreal, QC, Canada $u Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Würnschimmel, Christoph $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Tian, Zhe $u Division of Urology, Cancer Prognostictables and Health Outcomes Unit, University of Montréal Health Center, Montreal, QC, Canada
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Departments of Urology, Weill Cornell Medical College, New York, NY, USA $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prag, Czech Republic $u Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia $u Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan
700    1_
$a Saad, Fred $u Division of Urology, Cancer Prognostictables and Health Outcomes Unit, University of Montréal Health Center, Montreal, QC, Canada
700    1_
$a Briganti, Alberto $u Department of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Tilki, Derya $u Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany $u Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Banek, Severine $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Theodor- Stern Kai 7, 60590, Frankfurt am Main, Germany
700    1_
$a Kluth, Luis A $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Theodor- Stern Kai 7, 60590, Frankfurt am Main, Germany
700    1_
$a Roos, Frederik C $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Theodor- Stern Kai 7, 60590, Frankfurt am Main, Germany
700    1_
$a Chun, Felix K H $u Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Theodor- Stern Kai 7, 60590, Frankfurt am Main, Germany
700    1_
$a Karakiewicz, Pierre I $u Division of Urology, Cancer Prognostictables and Health Outcomes Unit, University of Montréal Health Center, Montreal, QC, Canada
773    0_
$w MED00001035 $t Cancer causes & control : CCC $x 1573-7225 $g Roč. 33, č. 1 (2022), s. 25-35
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34476653 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506125820 $b ABA008
999    __
$a ok $b bmc $g 1789164 $s 1162631
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 33 $c 1 $d 25-35 $e 20210902 $i 1573-7225 $m Cancer causes & control $n Cancer Causes Control $x MED00001035
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace